ATE348155T1 - Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren - Google Patents

Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren

Info

Publication number
ATE348155T1
ATE348155T1 AT97950677T AT97950677T ATE348155T1 AT E348155 T1 ATE348155 T1 AT E348155T1 AT 97950677 T AT97950677 T AT 97950677T AT 97950677 T AT97950677 T AT 97950677T AT E348155 T1 ATE348155 T1 AT E348155T1
Authority
AT
Austria
Prior art keywords
yields
production
purification
serum
cell culture
Prior art date
Application number
AT97950677T
Other languages
English (en)
Inventor
Shuyuan Zhang
Capucine Twin
Zheng Wu
Toohyoon Cho
Lucetta Caston
Deborah Wilson
Original Assignee
Introgen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21858843&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE348155(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Introgen Therapeutics Inc filed Critical Introgen Therapeutics Inc
Application granted granted Critical
Publication of ATE348155T1 publication Critical patent/ATE348155T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
AT97950677T 1996-11-20 1997-11-20 Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren ATE348155T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3132996P 1996-11-20 1996-11-20

Publications (1)

Publication Number Publication Date
ATE348155T1 true ATE348155T1 (de) 2007-01-15

Family

ID=21858843

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97950677T ATE348155T1 (de) 1996-11-20 1997-11-20 Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
AT06025694T ATE550429T1 (de) 1996-11-20 1997-11-20 Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06025694T ATE550429T1 (de) 1996-11-20 1997-11-20 Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren

Country Status (15)

Country Link
US (7) US6194191B1 (de)
EP (3) EP1760151B1 (de)
JP (1) JP4492826B2 (de)
KR (1) KR100503701B1 (de)
CN (1) CN1244215B (de)
AT (2) ATE348155T1 (de)
AU (1) AU732703B2 (de)
BR (1) BR9713368A (de)
CA (1) CA2272820C (de)
DE (1) DE69737107T2 (de)
ES (2) ES2278399T3 (de)
HK (1) HK1107116A1 (de)
NO (1) NO992389L (de)
NZ (1) NZ335947A (de)
WO (1) WO1998022588A2 (de)

Families Citing this family (253)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008298A1 (en) * 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
US20020088014A1 (en) * 1996-05-31 2002-07-04 Xiangming Fang Minimal adenovirus mediated recombinant vaccine
BR9710030A (pt) 1996-07-01 1999-08-10 Rhone Poulenc Rorer Sa Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida]
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
ES2278399T3 (es) * 1996-11-20 2007-08-01 Introgen Therapeutics, Inc. Metodo mejorado para la produccion y purificacion de vectores adenovirales.
US6544769B1 (en) 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US6995006B2 (en) * 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
NZ504214A (en) * 1997-10-24 2003-06-30 Invitrogen Corp Recombination cloning using nucleic acids having recombination sites
US7705602B2 (en) * 1997-11-03 2010-04-27 Midtronics, Inc. Automotive vehicle electrical system diagnostic device
US20040204381A1 (en) * 1997-11-12 2004-10-14 Moskal Joseph R Detection and treatment of glyco-enzyme-related disease
US6899870B1 (en) * 1998-03-11 2005-05-31 Board Of Regents, The University Of Texas System Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
EP1073721B1 (de) * 1998-04-22 2005-08-31 Genvec, Inc. Effiziente reinigung von adenovirus
US6416992B1 (en) * 1998-10-13 2002-07-09 Avigen, Inc. Compositions and methods for producing recombinant adeno-associated virus
US7691370B2 (en) * 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
WO2000029024A1 (en) * 1998-11-16 2000-05-25 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US7148035B1 (en) * 1998-11-18 2006-12-12 Oxford Biomedica (Uk) Limited Polypeptide
US6210922B1 (en) * 1998-11-30 2001-04-03 National Research Council Of Canada Serum free production of recombinant proteins and adenoviral vectors
FR2788064B1 (fr) * 1998-12-31 2003-01-31 Aventis Pharma Sa Methode de separation de particules virales
EP1141249A1 (de) 1998-12-31 2001-10-10 Aventis Pharma S.A. Methode zur trennung von viruspartikeln
US7264958B1 (en) 1999-02-22 2007-09-04 Transgene, S.A. Method for obtaining a purified viral preparation
US6795585B1 (en) 1999-07-16 2004-09-21 Eastman Kodak Company Representing digital images in a plurality of image processing states
JP2003518380A (ja) * 1999-12-29 2003-06-10 ジェンザイム・コーポレイション 核酸および他の細胞性汚染混入物質からウイルスベクターを分離するための濾過助剤の使用方法
US6168941B1 (en) * 2000-04-07 2001-01-02 Genvec, Inc. Method of producing adenoviral vector stocks
EP1280409A4 (de) * 2000-04-28 2004-05-19 Zengen Inc Ein gentherapie-system und ein verfahren, das alpha-msh und seine derivate verwendet
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US20020064860A1 (en) * 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
MXPA03007535A (es) * 2001-03-16 2003-12-11 Oncolytics Biotech Inc Metodo para extraer virus de cultivo celular.
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
NZ528462A (en) * 2001-03-27 2005-11-25 Vertex Pharma Compositions and methods useful for HCV infection
EP1427835B1 (de) 2001-08-08 2016-01-20 The Trustees of the University of Pennsylvania Verfahren zur reinigung von virusvektoren mit sialinsäure bindenden proteinen
US20040253210A1 (en) * 2001-08-30 2004-12-16 Marjorie Robert-Guroff Adenovirus type7 vectors
WO2003023026A1 (en) * 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
WO2003039459A2 (en) * 2001-11-05 2003-05-15 Genvec, Inc. Viral vector production methods and compositions
EP1407006B9 (de) * 2001-12-20 2006-10-18 Bavarian Nordic A/S Methode zur gewinnung und reinigung von poxviren aus infizierten zellen
KR100451308B1 (ko) * 2001-12-28 2004-10-06 선바이오(주) 단백질 의약품 정제 방법에서의 바이러스 제거 방법
WO2003068804A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Novel insect cell line
AU2003213072A1 (en) * 2002-02-20 2003-09-09 Merck And Co., Inc. Method of determining adenovirus particle concentration
US20030175688A1 (en) * 2002-03-15 2003-09-18 Rukmini Pennathur-Das Method for the purification and production of oncolytic adenoviruses
US20030186832A1 (en) * 2002-03-15 2003-10-02 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Isotropic liquid detergents with improved anti-redeposition
US20030180936A1 (en) * 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
JP2005521417A (ja) * 2002-03-29 2005-07-21 メルク　エンド　カムパニー　インコーポレーテッド アデノウイルスの大規模産生方法及びアデノウイルス種子ストック
EP1501921B2 (de) * 2002-04-30 2012-07-25 Oncolytics Biotech Inc. Verbesserte reinigungsmethode für viren
ES2357366T3 (es) * 2002-05-14 2011-04-25 MERCK SHARP & DOHME CORP. Procedimientos de purificación de adenovirus.
US20030224354A1 (en) * 2002-05-30 2003-12-04 Introgen Therapeutics Inc. Quantifying viral particles with intrinsic fluorescence
EP1371723A1 (de) * 2002-06-12 2003-12-17 Procorde GmbH Verfahren zur Herstellung von einer Adenoviruszubereitung
WO2004009768A2 (en) * 2002-07-18 2004-01-29 Invitrogen Corporation Viral vectors containing recombination sites
US20040106184A1 (en) * 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
KR20110050745A (ko) * 2002-10-03 2011-05-16 탈자진 인코포레이티드 혈관항상성 유지제 및 그의 사용 방법
AU2003298594A1 (en) * 2002-11-01 2004-06-07 Promega Corporation Cell lysis compositions, methods of use, apparatus, and kit
JP4991108B2 (ja) 2002-12-13 2012-08-01 アルファバックス，インコーポレイティド 多抗原性アルファウイルス・レプリコン粒子及び方法
CA2509979C (en) * 2002-12-13 2013-02-26 Alphavax, Inc. Alphavirus particles and methods for preparation
EP2181704B1 (de) 2002-12-30 2015-05-06 Angiotech International Ag Wirkstofffreisetzung von schnell gelierender Polymerzusammensetzung
EP1594433B8 (de) 2003-01-14 2016-12-21 Dana-Farber Cancer Institute, Inc. Sensibilisator für krebstherapie
JP5016305B2 (ja) * 2003-03-20 2012-09-05 アルファヴァックス，インコーポレイテッド 改良されたアルファウイルスレプリコンおよびヘルパー構築物
ES2290705T3 (es) * 2003-05-01 2008-02-16 Dsm Ip Assets B.V. Proceso para la produccion de sustancias biologicas por cultivo por perfusion de celulas animales suspendidas.
US20040229335A1 (en) * 2003-05-15 2004-11-18 Introgen Therapeutics, Inc. Methods and compositions for the production of adenoviral vectors
CA2529053A1 (en) * 2003-06-18 2004-12-29 Onyx Pharmaceuticals, Inc. Method for purifying virus
ATE432285T1 (de) * 2003-07-11 2009-06-15 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
CA2531773A1 (en) 2003-07-21 2005-02-17 Transgene S.A. Novel multifunctional cytokines
EP1697534B1 (de) 2003-12-01 2010-06-02 Life Technologies Corporation Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
EP1697505A1 (de) * 2003-12-23 2006-09-06 Schering Corporation Methoden zur herstellung von a549 zelllinien, die in serumfreiem medium in suspensionskultur stabil sind
ES2329607T3 (es) * 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
CN100333797C (zh) * 2005-01-26 2007-08-29 彭朝晖 重组腺病毒p53制品在肿瘤治疗中的新用途
AU2005231507B2 (en) * 2004-04-08 2012-03-01 Targegen, Inc. Benzotriazine inhibitors of kinases
DK1751289T3 (da) * 2004-05-18 2009-05-11 Alphavax Inc TC-83-afledte alfavirus-vektorer, partikler og fremgangsmåder
EP4170024A1 (de) * 2004-06-01 2023-04-26 Genzyme Corporation Zusammensetzungen und verfahren zur verhinderung der aav-vektoraggregation
US20050287616A1 (en) * 2004-06-29 2005-12-29 Gross Adam F Method of assaying denaturation of proteins
NZ588896A (en) 2004-08-25 2012-05-25 Targegen Inc Heterocyclic compounds and methods of use
DE202004014949U1 (de) * 2004-09-25 2004-11-18 Techno-Grafica Gmbh Vorrichtung zum Wärmebehandeln einer Beschichtung von Flachoffset-Druckplatten
DE102004049290A1 (de) * 2004-10-09 2006-04-20 Bayer Healthcare Ag Verfahren zur Herstellung von Virusmaterial
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
CN101080488A (zh) * 2004-11-03 2007-11-28 因特罗根治疗公司 生产和纯化腺病毒载体的新方法
CN100497640C (zh) * 2004-11-26 2009-06-10 中国人民解放军军事医学科学院生物工程研究所 一种高效生产重组腺病毒载体的方法
US20060166364A1 (en) * 2004-12-22 2006-07-27 Introgen, Inc. Use of flexible bag containers for viral production
ES2382557T3 (es) * 2004-12-23 2012-06-11 Medimmune, Llc Línea celular MDCK no tumorigénica para propagar virus
US20060205080A1 (en) * 2005-03-01 2006-09-14 David Frey Formulations for therapeutic viruses having enhanced storage stability
EA015584B1 (ru) 2005-03-23 2011-10-31 Генмаб А/С Антитело к cd38 человека и его применение
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
US20060263415A1 (en) * 2005-05-05 2006-11-23 Sensient Flavors Inc. Production of beta-glucans and mannans
JP2008543775A (ja) * 2005-06-08 2008-12-04 ターゲジェン インコーポレーティッド 眼の障害を治療するための方法および組成物
WO2007005885A2 (en) * 2005-07-05 2007-01-11 David Nance Energy recovery within a fluid distribution network using geographical information
MY167260A (en) * 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
PL2005185T3 (pl) * 2006-03-22 2011-05-31 Viral Logic Systems Tech Corp Sposoby identyfikowania celów polipeptydowych
WO2007127366A2 (en) * 2006-04-25 2007-11-08 Targegen, Inc. Kinase inhibitors and methods of use thereof
ES2473275T3 (es) * 2006-09-15 2014-07-04 Medimmune, Llc Líneas de células MDCK que soportan el crecimiento viral hasta altos títulos y proceso de biorreactor que las usa.
PL2118292T3 (pl) 2007-01-30 2011-12-30 Transgene Sa Polipeptyd E2 wirusa brodawczaka stosowany do szczepienia
US20080299624A1 (en) * 2007-06-01 2008-12-04 Edward Heslop Continuous fermentation apparatus and method
DK2183368T3 (en) 2007-06-21 2016-09-05 Alphavax Inc PROMOTER-FREE CASES FOR EXPRESSION OF ALPHAVIRUS STRUCTURE PROTEINS
EP2207874B1 (de) * 2007-10-08 2014-12-03 Intrexon Corporation Technisch manipulierte dendritische zellen und verwendungen zur krebsbehandlung
WO2009058564A2 (en) 2007-11-01 2009-05-07 Maxygen, Inc. Immunosuppressive polypeptides and nucleic acids
US20090253184A1 (en) * 2008-01-23 2009-10-08 Introgen Therapeutics, Inc. Compositions and methods related to an adenoviral trans-complementing cell line
CA2723726C (en) * 2008-05-13 2017-09-12 Michael M. Becker Inactivatable target capture oligomers for use in the selective hybridization and capture of target nucleic acid sequences
PL3192874T3 (pl) * 2008-06-18 2020-06-29 Oxford Biomedica (Uk) Limited Oczyszczanie wirusa
AU2009296628B2 (en) 2008-09-24 2015-01-15 Medimmune, Llc Methods for purification of viruses
RU2015103990A (ru) * 2008-09-24 2015-10-27 Медиммун, Ллк Способы культивирования клеток, размножения и очистки вирусов
CA2742474C (en) 2008-11-03 2016-05-31 Crucell Holland B.V. Method for the production of adenoviral vectors
WO2010062757A1 (en) * 2008-11-03 2010-06-03 Ligocyte Pharmaceuticals, Inc. Improved methods for isolating enveloped virus-based vlps free of infectious agents
WO2010136979A2 (en) * 2009-05-26 2010-12-02 Leviathan Energy Hydroelectric Ltd. Hydroelectric in-pipe turbine uses
CN103335945A (zh) * 2009-07-07 2013-10-02 索尼公司 微流体装置
MX2012001592A (es) 2009-08-07 2012-05-22 Transgene Sa Composicion para el tratamiento de la infección del virus de la hepatitis b.
EA028623B1 (ru) 2009-10-15 2017-12-29 Янссен Вэксинс Энд Превеншн Б.В. Способ очистки аденовирусных частиц
BR112012008507B8 (pt) 2009-10-15 2021-05-25 Crucell Holland Bv método para purificar partículas de adenovírus a partir de uma suspensão de célula
DK2521776T3 (en) 2010-01-05 2017-02-13 Vascular Biogenics Ltd METHODS FOR USING A SPECIFIC ANTI-ANGIOGENT ADENOVIRAL AGENT
WO2011083466A1 (en) 2010-01-05 2011-07-14 Vascular Biogenics Ltd. Compositions and methods for treating glioblastoma gbm
WO2011086509A1 (en) * 2010-01-12 2011-07-21 Vascular Biogenics Ltd. Methods of producing adenovirus vectors and viral preparations generated thereby
CN102762721B (zh) 2010-02-15 2015-03-11 克鲁塞尔荷兰公司 用于生产Ad26腺病毒载体的方法
SG184833A1 (en) * 2010-04-14 2012-11-29 Emd Millipore Corp Methods of producing high titer, high purity virus stocks and methods of use thereof
WO2012019354A1 (en) 2010-08-12 2012-02-16 Yisheng Biopharma Holdings Ltd. Method for reducing dna impurities in viral compositions
CA2808556A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
EP2461162A1 (de) 2010-12-03 2012-06-06 Texcell, . Verfahren zur Bestimmung des Titers von Viren durch Verwendung von infektiösen Standardsubstanzen
CN103476928B (zh) 2010-12-09 2017-03-29 巴斯德研究所 用于获得高产量重组蛋白表达的基于mgmt的方法
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
TW201321016A (zh) 2011-09-29 2013-06-01 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（二）
WO2013045658A1 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
CN104379733B (zh) 2012-03-12 2016-01-20 克鲁塞尔荷兰公司 具改变末端的重组腺病毒群
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
WO2013139911A1 (en) 2012-03-22 2013-09-26 Crucell Holland B.V. Vaccine against rsv
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
ES2740004T3 (es) * 2012-07-26 2020-02-05 Flash Therapeutics Método para detectar o medir el impacto de una composición de vector vírico en células eucariotas y sus biomarcadores utilizados
JP6430949B2 (ja) 2012-10-23 2018-11-28 エモリー ユニバーシティ Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
EA039803B1 (ru) 2013-04-25 2022-03-15 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные растворимые f-полипептиды rsv до слияния
WO2014179108A1 (en) 2013-05-03 2014-11-06 Honeywell International Inc. Lead frame construct for lead-free solder connections
SG11201510216RA (en) 2013-06-17 2016-01-28 Crucell Holland Bv Stabilized soluble pre-fusion rsv f polypeptides
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
CN105658806A (zh) * 2013-10-30 2016-06-08 默克专利股份公司 从复杂样品中分离微生物的方法
JP2017509489A (ja) 2014-02-20 2017-04-06 ハネウェル・インターナショナル・インコーポレーテッド 鉛フリーはんだ組成物
JP6783143B2 (ja) 2014-03-25 2020-11-11 テルモ ビーシーティー、インコーポレーテッド 培地の受動的補充
EA201691696A1 (ru) 2014-04-25 2017-03-31 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
CN105316296A (zh) * 2014-06-13 2016-02-10 亚宝药业太原制药有限公司 一种纯化腺病毒颗粒的方法
WO2016040441A1 (en) 2014-09-09 2016-03-17 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
GB201417042D0 (en) * 2014-09-29 2014-11-12 Fkd Therapies Oy Method
CN112553229A (zh) 2014-11-05 2021-03-26 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
CN107207556B (zh) 2014-11-14 2020-12-08 沃雅戈治疗公司 调节性多核苷酸
RU2020108189A (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
CN107428799A (zh) 2015-01-13 2017-12-01 阿尔法韦士曼公司 纯化腺相关病毒(AAV)及/或重组腺相关病毒(rAAV)之方法及其梯度和流通式缓冲液
EP3054007A1 (de) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Reinigung von rekombinanten, adeno-assoziierten viren mit einem immunaffinen reinigungsschritt
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
US10570417B2 (en) 2015-04-14 2020-02-25 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017005848A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
US10456462B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Preventions B.V. Vaccine against RSV
US9663766B2 (en) 2015-07-24 2017-05-30 Bio-Rad Laboratories, Inc. Methods for purifying adenovirus vectors
MX2018004546A (es) 2015-10-16 2019-04-15 Univ Columbia Composiciones y métodos para la inhibicion de antígenos específicos de linaje.
WO2017075335A1 (en) 2015-10-28 2017-05-04 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
CN109069612A (zh) 2016-04-05 2018-12-21 扬森疫苗与预防公司 针对rsv的疫苗
PL3439672T3 (pl) 2016-04-05 2021-06-14 Janssen Vaccines & Prevention B.V. Stabilizowane rozpuszczalne białko f rsv przed fuzją do zastosowania w profilaktyce zakażenia rsv
KR102535013B1 (ko) * 2016-04-14 2023-05-22 트리젤 엘티디. 정유량 펌프/튜빙 시스템이 있는 고정층 바이오 리액터
KR20230022177A (ko) * 2016-04-14 2023-02-14 트리젤 엘티디. 정유량 펌프/튜빙 시스템이 있는 고정층 바이오 리액터
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (de) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Zusammensetzungen zur behandlung einer erkrankung
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US11951121B2 (en) 2016-05-18 2024-04-09 Voyager Therapeutics, Inc. Compositions and methods for treating Huntington's disease
JP7066635B2 (ja) 2016-05-18 2022-05-13 ボイジャー セラピューティクス インコーポレイテッド 調節性ポリヌクレオチド
JP2019523644A (ja) 2016-05-30 2019-08-29 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された融合前ｒｓｖ ｆタンパク質
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
EP3472327B1 (de) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potenter und ausbalancierter bidirektionaler promotor
WO2018011196A1 (en) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Hpv vaccines
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018080573A1 (en) 2016-10-28 2018-05-03 Massachusetts Institute Of Technology Crispr/cas global regulator screening platform
CN108085301B (zh) * 2016-11-22 2021-10-26 贺道耀 从宿主细胞提取和纯化腺相关病毒和腺病毒的方法及其组分和试剂盒
US10294452B2 (en) 2016-11-22 2019-05-21 Dao-Yao He Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
WO2018106888A1 (en) * 2016-12-08 2018-06-14 Temple University-Of The Commonwealth System Of Higher Education Small animal models for in vivo testing of polyomavirus therapeutics
WO2018148246A1 (en) 2017-02-07 2018-08-16 Massachusetts Institute Of Technology Methods and compositions for rna-guided genetic circuits
EP3656841A1 (de) 2017-03-31 2020-05-27 Terumo BCT, Inc. Zellexpansion
US11752181B2 (en) 2017-05-05 2023-09-12 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease
JP2020518258A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN111132626B (zh) 2017-07-17 2024-01-30 沃雅戈治疗公司 轨迹阵列引导***
WO2019028306A2 (en) 2017-08-03 2019-02-07 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES
CN107384873A (zh) * 2017-09-05 2017-11-24 成都汇宇生物技术有限公司 重组腺病毒的纯化方法
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
AU2018352236A1 (en) 2017-10-16 2020-04-23 The Curators Of The University Of Missouri Treatment of amyotrophic lateral sclerosis (ALS)
EP3707250A1 (de) * 2017-11-08 2020-09-16 Blue Sky Vaccines GmbH So3-chromatographie zur verwendung in einem verfahren zur virusreinigung
US20210010028A1 (en) 2018-03-06 2021-01-14 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
CN112313331A (zh) 2018-04-27 2021-02-02 沃雅戈治疗公司 用于测量aadc病毒载体效力的方法
TW202015742A (zh) 2018-05-15 2020-05-01 美商航海家醫療公司 投遞腺相關病毒（ａａｖ）之組成物和方法
JP2021523914A (ja) 2018-05-15 2021-09-09 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． パーキンソン病を治療するための組成物および方法
WO2019222441A1 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
EP3793615A2 (de) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Gerichtete entwicklung von aav zur verbesserung des tropismus für zns
CA3103963A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
MX2021000810A (es) 2018-07-24 2021-04-28 Voyager Therapeutics Inc Sistemas y metodos para producir formulaciones de terapia genetica.
BR112021003670A2 (pt) 2018-08-28 2021-05-18 Vor Biopharma, Inc. células-tronco hematopoéticas geneticamente modificadas e seus usos
EP3861010A1 (de) 2018-10-02 2021-08-11 Voyager Therapeutics, Inc. Umlenkung des tropismus von aav-kapsiden
WO2020072849A1 (en) 2018-10-04 2020-04-09 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
US20210371470A1 (en) 2018-10-12 2021-12-02 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
EP3876953A4 (de) * 2018-12-11 2022-10-19 ERBI Biosystems, Inc. Verfahren zur herstellung von zellbasierten produkten unter verwendung von perfusionsprozessen mit kleinem volumen
SG11202107645RA (en) 2019-01-18 2021-08-30 Voyager Therapeutics Inc Methods and systems for producing aav particles
US11542526B2 (en) 2019-02-21 2023-01-03 Unleash Immuno Oncolytics, Inc. Oncolytic adenoviral vector and methods of use
CN110093455B (zh) * 2019-04-27 2020-03-17 中国医学科学院病原生物学研究所 一种呼吸道病毒的检测方法
WO2020223274A1 (en) 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
EP3966227A1 (de) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur vektorisierten vermehrung von proteinzerstörung, -expression und/oder -regulierung
CN112175996A (zh) * 2019-07-05 2021-01-05 杭州荣泽生物科技有限公司 一种基因治疗载体的制备方法和用途
EP4010465A1 (de) 2019-08-09 2022-06-15 Voyager Therapeutics, Inc. Zellkulturmedium zur verwendung bei der herstellung von gentherapieprodukten in bioreaktoren
TW202122582A (zh) 2019-08-26 2021-06-16 美商航海家醫療公司 病毒蛋白之控制表現
US20220333133A1 (en) 2019-09-03 2022-10-20 Voyager Therapeutics, Inc. Vectorized editing of nucleic acids to correct overt mutations
US20210147779A1 (en) * 2019-11-15 2021-05-20 City Of Hope System, device and method for production of bioproduct including high density cell respirator (hdcr) for intensified production of adeno-associated viruses (aav) and cell-based production
CN110894494B (zh) * 2019-11-22 2022-09-27 广西梧州制药（集团）股份有限公司 一种大规模高密度悬浮培养293细胞高产腺病毒的方法
WO2021202651A1 (en) 2020-04-01 2021-10-07 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
CA3180222A1 (en) 2020-04-15 2021-10-21 Voyager Therapeutics, Inc. Tau binding compounds
GB202005732D0 (en) 2020-04-20 2020-06-03 Synpromics Ltd Regulatory nucleic acid sequences
CN116096734A (zh) 2020-05-13 2023-05-09 沃雅戈治疗公司 Aav衣壳的向性的重定向
EP4192514A1 (de) 2020-08-06 2023-06-14 Voyager Therapeutics, Inc. Zellkulturmedium zur verwendung bei der herstellung von gentherapieprodukten in bioreaktoren
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
CN112226418B (zh) * 2020-09-25 2022-07-08 阜外华中心血管病医院 重组腺相关病毒纯化方法
EP4225382A2 (de) 2020-10-07 2023-08-16 Asklepios Biopharmaceutical, Inc. Therapeutische adeno-assoziierte virusverabreichung von fkutin-verwandtem protein (fkrp) zur behandlung von dystroglycanopathie. erkrankungen mit gliedmassengürtel 21
CN112293394B (zh) * 2020-10-30 2022-11-25 海南德安欣有害生物防治科技有限公司 一种捕鼠装置及捕鼠方法
KR20230078805A (ko) 2020-11-02 2023-06-02 바이오마린 파머수티컬 인크. 아데노-연관 바이러스의 농축 공정
GB202019454D0 (en) * 2020-12-10 2021-01-27 Chancellor Masters And Scholars Of The Univ Of Oxford Method for purifying virus
WO2022187473A2 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2023034989A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034990A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034994A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034997A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034980A1 (en) 2021-09-03 2023-03-09 Bomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034996A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
CA3232833A1 (en) 2021-09-27 2023-03-30 Kathleen Mcginness Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
WO2023081648A1 (en) 2021-11-02 2023-05-11 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2023091909A1 (en) 2021-11-16 2023-05-25 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients
WO2023091948A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2023111580A1 (en) 2021-12-16 2023-06-22 University Of Dundee Targeted degradation of alpha-synuclein
WO2023147374A2 (en) 2022-01-25 2023-08-03 Voyager Therapeutics, Inc. Baculovirus expression system
WO2023154693A1 (en) 2022-02-08 2023-08-17 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
GB202201713D0 (en) 2022-02-10 2022-03-30 Univ Dundee An affinity directed phosphatase system for targeted protein dephosphorylation
CN115354033A (zh) * 2022-03-25 2022-11-18 上海碧博生物医药科技有限公司 一种细胞裂解液、细胞裂解方法及该方法在收获aav的应用
WO2023235791A1 (en) 2022-06-02 2023-12-07 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2024006741A1 (en) 2022-06-28 2024-01-04 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2024011112A1 (en) 2022-07-06 2024-01-11 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2024040208A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2024059739A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. Tau binding compounds
WO2024064856A1 (en) 2022-09-22 2024-03-28 Biomarin Pharmaceutical Inc. Treatment of cardiomyopathy with aav gene therapy vectors
WO2024064863A2 (en) 2022-09-22 2024-03-28 Biomarin Pharmaceutical Inc. Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
CN117551624A (zh) * 2024-01-11 2024-02-13 深圳源兴基因技术有限公司 一种基于无血清悬浮扩增的高效回收腺病毒的方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US789244A (en) * 1902-10-01 1905-05-09 Hans Thormeyer Steam-turbine.
US824544A (en) * 1905-12-04 1906-06-26 George Hossege Pipe-hanger.
US4222743A (en) 1978-07-20 1980-09-16 Wang Wei Kung Method and apparatus for detecting biological particles by fluorescent stain
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4539020A (en) * 1983-07-10 1985-09-03 Kawasaki Steel Corporation Methods for obtaining high-purity carbon monoxide
JPS6147187A (ja) 1984-08-10 1986-03-07 Chemo Sero Therapeut Res Inst 狂犬病ウイルスの精製方法
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5173418A (en) * 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5106841A (en) * 1986-05-13 1992-04-21 Chai-Tech Corporation Antiviral compositions and method for their use
EP0273085A1 (de) 1986-12-29 1988-07-06 IntraCel Corporation Verfahren zur Einführung fremder Nukleinsäuren in eukaryotische Zellen
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
JPH0761955B2 (ja) 1988-04-28 1995-07-05 国立予防衛生研究所長 凍結乾燥ａ型肝炎ワクチン
US5219752A (en) * 1988-05-25 1993-06-15 Teijin, Limited Process for continuously culturing adherent animal cells
DE59006065D1 (en) 1989-01-16 1994-07-14 Telefunken Fernseh & Rundfunk Kompatibles frequenzmultiplex-fernsehsystem.
EP0470982B1 (de) 1989-05-01 1993-07-14 BOHNENKAMP, Wolfram Reflexionsfluorimeter
WO1991009310A1 (en) 1989-12-12 1991-06-27 Lidak Pharmaceuticals Free fatty acid determination
IT1238231B (it) 1989-12-18 1993-07-12 Consiglio Nazionale Ricerche Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
NO312681B1 (no) 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
IT1248075B (it) 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
DE69326967T2 (de) 1992-01-17 2000-06-15 Lakowicz Joseph R Phasenmodulationsenergieübertragungsfluoroimmunassay
US5323008A (en) 1992-03-23 1994-06-21 Diatron Corporation Fluorometer detection system
AU673827B2 (en) 1992-03-24 1996-11-28 United Cancer Research Institute Vaccine containing live virus for therapy of viral diseases and malignancies
US5428011A (en) 1992-06-16 1995-06-27 Procyon Biopharma, Inc. Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma
US5733720A (en) 1992-06-18 1998-03-31 Washington University Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor
WO1994002638A1 (en) * 1992-07-17 1994-02-03 Aprogenex, Inc. Free radical scavengers useful for reducing autofluorescence in fixed cells
CA2144848A1 (en) 1992-09-18 1994-03-31 H. Michael Shepard Gene therapy by retroviral vector with tumor suppressive gene
US5733721A (en) * 1992-11-20 1998-03-31 The Board Of Regents Of The University Of Oklahoma Cell analysis method using quantitative fluorescence image analysis
JP3246664B2 (ja) 1993-01-29 2002-01-15 ニュー ブルンズウイック サイエンティフィック カンパニー インコーポレイテッド 足場および懸濁細胞の培養方法並びにその装置
US5604096A (en) * 1993-03-04 1997-02-18 Schaeffer; Warren I. Fluorometric quantitation of mycoplasmas
US5994314A (en) 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
EP0655091A1 (de) 1993-05-06 1995-05-31 Baxter Diagnostics Inc. Nachweismethode des menschlichen papillomavirus
US5421339A (en) * 1993-05-12 1995-06-06 Board Of Regents, The University Of Texas System Diagnosis of dysplasia using laser induced fluoroescence
US6686200B1 (en) * 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
AU7971194A (en) 1993-10-12 1995-05-04 Chiron Corporation Methods for preserving recombinant viruses
TW442569B (en) * 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
EP0738319A4 (de) * 1994-01-12 2000-03-29 Genetic Therapy Inc Reinigung von retroviralen Vektoren
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
US5498537A (en) * 1994-03-09 1996-03-12 Cellco, Inc. Serum-free production of packaged viral vector
WO1995025789A1 (en) * 1994-03-22 1995-09-28 The Immune Response Corporation Highly efficient production and isolation of viral particles
US5521083A (en) * 1994-05-13 1996-05-28 The Research Foundation Of State University Of New York Et Al. Large granular lymphocyte leukemia associated virus
AU3551195A (en) * 1994-09-23 1996-04-09 Somatix Therapy Corporation Chimeric adenovirus for gene delivery
US5552309A (en) 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US5744304A (en) * 1995-05-30 1998-04-28 Board Of Regents, The University Of Texas System Inflammation-induced expression of a recombinant gene
WO1997005480A1 (en) * 1995-07-27 1997-02-13 Massachusetts Institute Of Technology Separation and/or concentration of an analyte from a mixture using a two-phase aqueous micellar system
KR19990036028A (ko) * 1995-08-01 1999-05-25 다니엘 케르니 일본뇌염 백신의 공업적인 생산방법 및 이에 의한 백신
WO1997008298A1 (en) * 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
DK0863984T3 (da) 1995-11-30 2006-08-28 Univ Texas Fremgangsmåder og præparater til behandling af cancer
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
AR006240A1 (es) * 1996-03-14 1999-08-11 Fuller H B Licensing Financ Adhesivo de fusion caliente que comprende interpolimeros, articulo no tejido que lo comprende, procedimiento de polimerizacion para preparlo y caja, envase, bandeja y libro unidos con dicho adhesivo
JPH09262099A (ja) * 1996-03-28 1997-10-07 Aisin Seiki Co Ltd フルオレセイン誘導体リン酸エステルによる核酸等の検出方法
BR9710030A (pt) * 1996-07-01 1999-08-10 Rhone Poulenc Rorer Sa Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida]
ES2278399T3 (es) 1996-11-20 2007-08-01 Introgen Therapeutics, Inc. Metodo mejorado para la produccion y purificacion de vectores adenovirales.
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
CA2274876A1 (en) 1996-12-13 1998-06-18 Schering Corporation Method for purifying viruses
US6168944B1 (en) 1997-01-31 2001-01-02 Schering Corporation Methods for cultivating cells and propagating viruses
ATE361668T1 (de) 1997-02-18 2007-06-15 Canji Inc Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
US6130313A (en) 1997-10-02 2000-10-10 Clontech Laboratories, Inc. Rapidly degrading GFP-fusion proteins
KR100862169B1 (ko) 1998-02-17 2008-10-09 쉐링 코포레이션 바이러스를 포함하는 조성물
US5922576A (en) 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
CA2322202C (en) 1998-03-10 2010-11-30 Large Scale Proteomics Corporation Detection and characterization of microorganisms
US6265151B1 (en) 1998-03-27 2001-07-24 Seroptix, Inc. Apparatus and method for infectious disease detection
EP1073721B1 (de) 1998-04-22 2005-08-31 Genvec, Inc. Effiziente reinigung von adenovirus
US6171790B1 (en) 1998-05-01 2001-01-09 Incyte Pharmaceuticals, Inc. Human protease associated proteins
AU4188599A (en) 1998-05-15 1999-12-06 Geron Corporation Method and apparatus for detecting hazardous agents
JP3718430B2 (ja) 1998-06-30 2005-11-24 ラミナ，インコーポレイテッド 細胞および組織固定剤組成物および使用方法
AU5429399A (en) 1998-08-08 2000-02-28 Imperial Cancer Research Technology Limited Fluorescent assay for biological systems
US5965358A (en) * 1998-08-26 1999-10-12 Genvec, Inc. Method for assessing the relative purity of viral gene transfer vector stocks
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
EP1141249A1 (de) 1998-12-31 2001-10-10 Aventis Pharma S.A. Methode zur trennung von viruspartikeln
US6316185B1 (en) * 1999-09-29 2001-11-13 Mountain View Pharmaceuticals, Inc. Quantitation of viruses by light scattering
JP2002054561A (ja) * 2000-08-08 2002-02-20 Toyota Industries Corp 容量可変型圧縮機の制御弁及び容量可変型圧縮機
US6447995B1 (en) 2000-10-04 2002-09-10 Genvec, Inc. Utilizing intrinsic fluorescence to detect adenovirus
DE10050114A1 (de) * 2000-10-09 2002-04-25 Wolf Gmbh Richard Verwendung einer Gelmasse
US20040106184A1 (en) 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US20040229335A1 (en) * 2003-05-15 2004-11-18 Introgen Therapeutics, Inc. Methods and compositions for the production of adenoviral vectors

Also Published As

Publication number Publication date
CA2272820C (en) 2012-09-11
NZ335947A (en) 2000-12-22
US6194191B1 (en) 2001-02-27
ES2278399T3 (es) 2007-08-01
EP1707631A2 (de) 2006-10-04
US20030008375A1 (en) 2003-01-09
NO992389L (no) 1999-07-19
EP0968284B1 (de) 2006-12-13
US7445930B2 (en) 2008-11-04
AU5361798A (en) 1998-06-10
DE69737107D1 (de) 2007-01-25
EP1760151A1 (de) 2007-03-07
US20100055763A1 (en) 2010-03-04
US20050089999A1 (en) 2005-04-28
NO992389D0 (no) 1999-05-19
CN1244215B (zh) 2010-11-03
US7510875B2 (en) 2009-03-31
BR9713368A (pt) 2001-09-18
CA2272820A1 (en) 1998-05-28
DE69737107T2 (de) 2007-07-12
WO1998022588A2 (en) 1998-05-28
EP0968284A2 (de) 2000-01-05
HK1107116A1 (en) 2008-03-28
EP1707631A3 (de) 2006-12-27
JP4492826B2 (ja) 2010-06-30
EP1760151B1 (de) 2012-03-21
ES2383640T3 (es) 2012-06-25
AU732703B2 (en) 2001-04-26
US20020177215A1 (en) 2002-11-28
KR100503701B1 (ko) 2005-07-26
JP2001504701A (ja) 2001-04-10
CN1244215A (zh) 2000-02-09
WO1998022588A3 (en) 1998-10-15
ATE550429T1 (de) 2012-04-15
KR20000057160A (ko) 2000-09-15
US6726907B1 (en) 2004-04-27
US20070155008A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
ATE348155T1 (de) Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
ATE452183T1 (de) Eine verbesserte methode zur herstellung und reinigung von adenoviralen vektoren
ATE349542T1 (de) Zusammensetzungen und verfahren zur herstellung von helfer-freien rekombinanten adeno- assoziierten viren
ATE278789T1 (de) Hilfsfunktionen fuer die rekombinante aav- virionherstellung
DE69922934D1 (de) Zusammensetzungen und verfahren zur helfer-freien herstellung von rekombinante adeno-assoziierten viren
BR9913026A (pt) Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano
MY117686A (en) Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof
CA2415990A1 (en) Method for producing biologicals in protein-free culture
DK0733103T3 (da) Fremstilling af höje titre af rekombinante AAV vektorer
FI875082A0 (fi) Dna-sekvensser deriverade fraon genom av papillomavirus, deras anvaendning foer in vitro diagnostiska aendamaol; samt framstaellning av antigeniska kompositioner.
DK0904351T3 (da) Dyreceller og fremgangsmåder til replikationen af influenzavirus
DK0891420T3 (da) Fremgangsmåde til replikation af influenzavirus i cellekultur samt de ved fremgangsmåden opnåelige influenzavirus
DE69721840D1 (en) Zuckerrohr bacilliformviruspromotor
ATE414146T1 (de) Methoden zur herstellung von helpervirusfreien präparationen von freien rekombinenten aav- vektoren mit hohem titer
AU2768992A (en) Method for genetically modifying bone marrow cells of primates, and useful cells therefor that produce recombinant retroviral vectors
ATE369430T1 (de) Methoden zur herstellung von nukleotidintegrasen
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
WO2000004051A3 (en) Growth differentiation factor promoter and uses therefor
WO1998006827A3 (en) Method for immortalizing cells
Shapiro et al. A comparison of the membrane-bound and extracellular cyclic AMP phosphodiesterases of Dictyostelium discoideum
CA2289776A1 (en) An infectious clone for human parainfluenza virus type 3
WO1992014818A3 (en) Entomopoxvirus expression system comprising spheroidin or thymidine-kinase sequences
Harada et al. Orosomucoid 1 phenotyping from human urine by isoelectric focusing
Gawadi The spindle at metaphase
CA2250714A1 (en) Animal cells and processes for the replication of influenza viruses

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0968284

Country of ref document: EP

EEIH Change in the person of patent owner